The impact of sialic acids on the pharmacokinetics of a pegylated erythropoietin

Journal of Pharmaceutical Sciences

Volumn 101, Issue 12, 2012, Pages 4414-4418

  Liu, Liming ^a   Li, Huijuan ^a   Hamilton, Stephen R ^a   Gomathinayagam, Sujatha ^a   Rayfield, William J ^a   van Maanen, Marc ^a   Yin, Kuo Chang ^a   Hong, Laura ^a   Prueksaritanont, Thomayant ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biotechnology; Clearance; Glycosylation; Pegylation; Pharmacokinetics

Indexed keywords

EID: 84868204025     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23320     Document Type: Article

References (15)

1. Spivak JL. 1998. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 25:7-11.
2. Takeuchi M, Inoue N, Strickland TW, Kubota M, Wada M, Shimizu R, Hoshi S, Kozutsumi H, Takasaki S, Kobata A. 1989. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 86:7819-7822.
3. Takeuchi M, Kobata A. 1991. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:337-346.
4. Skibeli V, Nissen-Lie G, Torjesen P. 2001. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98:3626-3634.
5. Egrie JC, Browne JK. 2002. Development and characterization of darbepoetin alfa. Oncology (Williston Park) 16:13-22.
6. Macdougall IC, Padhi D, Jang G. 2007. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 22 Suppl 4:iv2-iv9.
7. Roopenian DC, Akilesh S. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
8. Beck A, Reichert JM. 2011. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3:415-416.
9. Macdougall IC. 2005. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436-440.
10. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. 2003. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299.
11. Nett JH, Gomathinayagam S, Hamilton SR, Gong B, Davidson RC, Du M, Hopkins D, Mitchell T, Mallem MR, Nylen A, Shaikh SS, Sharkey N, Barnard GC, Copeland V, Liu L, Evers R, Li Y, Gray PM, Lingham RB, Visco D, Forrest G, DeMartino J, Linden T, Potgieter TI, Wildt S, Stadheim TA, d'Anjou M, Li H, Sethuraman N. 2012. Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris. J Biotechnol 157:198-206.
12. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
13. Jelkmann W. 2002. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69:265-274.
14. Egrie JC, Browne JK. 2001. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 Suppl 3:3-13.
15. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421.